银屑病生物制剂研发进展

The latest advances in the development of biologic agents for psoriasis

银屑病是一种免疫介导的慢性复发性炎症性皮肤病,随着对其免疫学发病机制的深入了解,针对特定靶点研发的生物制剂逐渐增多,因其临床疗效显著且安全性较高,临床应用也越来越普遍。当前生物科学迅速发展,生物制剂研发已进入了高速发展阶段,包括既有靶点的多种原研药齐头并进、双靶标的探索研发、纳米抗体和多肽的新技术开发等,本文对银屑病生物制剂的临床应用现状、研发中的生物制剂以及生物制剂的新靶点新结构等内容进行综述。

Psoriasis is a chronic immune⁃mediated inflammatory skin disease.A growing understanding of the mechanism has led to the advent of biological agents that specifically target the cytokines which are involved in the pathogenesis.Because of the significant efficacy with high safety shown in the treatment of psoriasis,biologic agents have becoming more and more usual in clinical practice.Rapid progress in biotechnology allows the development of an increasing number of novel biologic agents,such as biologics targeting existing and promising inflammatory mediators,bispecific agents targeting multiple different antigens and agents including nanobodies and peptides.This review summarizes the current application of biologic agents in clinical practice,new drugs that are under study,potential targets and novel technology of biologics.